Renin Unsuppression

How it works

Benefits

Comparisons

Evidence quality

Highlighted claims

• Renin unsuppression is presented as a direct physiological indicator that aldosterone blockade and reversal of volume excess have been achieved. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• It remains uncertain whether unsuppressed renin causes better outcomes or merely marks milder or more MRA-sensitive disease. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• RETAME-PA defines renin unsuppression using assay-specific thresholds because Canadian laboratories use both PRA and DRC assays without a reliable conversion between them. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• A retrospective cohort that titrated MRA to a PRA target greater than 1 ng/mL/hour achieved renin unsuppression in 82.1% of primary aldosteronism cases. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial
• Observational studies associate renin unsuppression during MRA therapy with better long-term cardiovascular and kidney outcomes. — Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) — a clinical research protocol for a randomised controlled trial